Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together cancer researchers, oncologists, and advocates to discuss the latest advances in cancer care. Some studies presented at ASCO may eventually change how uterine (endometrial) cancer is treated. Others help answer important questions patients have been asking for years.
This year, uterine (endometrial) cancer updates are drawing attention because they focus on issues patients care deeply about, including whether immunotherapy is improving long-term survival, how biomarker testing is shaping treatment decisions, and whether newer targeted therapies may offer additional options after recurrence.
Here are two uterine (endometrial) cancer updates patients and advocates should be paying attention to at ASCO 2026.
1. RUBY: Long-term survival outcomes with dostarlimab continue shaping frontline treatment
One of the most important shifts in uterine (endometrial) cancer treatment over the past several years has been the addition of immunotherapy to chemotherapy for patients with advanced or recurrent disease. The phase III RUBY trial evaluated dostarlimab (Jemperli) combined with carboplatin and paclitaxel followed by maintenance dostarlimab in patients with primary advanced or recurrent uterine (endometrial) cancer.
At ASCO 2026, researchers presented additional long-term survival analyses and cure modeling data from the RUBY trial. This update is important because earlier results already showed major improvements in progression-free survival and overall survival, especially for tumors that are mismatch repair deficient (dMMR) or MSI-high.
Key takeaways: After at least four years of follow-up, nearly 58% of patients treated with the combination were still alive without their cancer worsening, compared with about 16% of those who received chemotherapy alone. Researchers also found that more than half of patients treated with dostarlimab plus chemotherapy may have achieved long-lasting disease control consistent with a potential cure. These findings suggest that adding dostarlimab to chemotherapy can provide durable benefits and may help some patients remain cancer-free for many years. This study reinforces how dramatically immunotherapy has changed the treatment landscape in advanced endometrial cancer. It also highlights why biomarker testing, including MMR and MSI testing, has become increasingly important at diagnosis because these results may directly influence treatment options.
2. Pembrolizumab plus chemotherapy: Updated overall survival analysis in advanced endometrial cancer
Another important ASCO 2026 update focuses on pembrolizumab (Keytruda) combined with carboplatin and paclitaxel for patients with advanced or recurrent uterine (endometrial) cancer. Researchers presented updated overall survival results from the phase III NRG-GY018 trial, which previously showed that adding pembrolizumab to chemotherapy significantly improved progression-free survival in both mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) disease.
With longer follow-up, the study continued to show a meaningful survival benefit for patients who received pembrolizumab plus chemotherapy, even though many patients in the placebo group later received immunotherapy after their cancer progressed.
Key takeaways: In patients with dMMR tumors, 79% of patients treated with pembrolizumab were alive at 4 years compared with 60% in the placebo group. In the more common pMMR group, median overall survival improved from 35.1 months to 44.4 months with the addition of pembrolizumab.
This update is important because overall survival is considered one of the most meaningful measures in cancer research. Patients and oncologists want to know not only whether a treatment delays progression, but whether patients ultimately live longer. The findings from NRG-GY018 continue to strengthen the role of immunotherapy plus chemotherapy as a frontline treatment standard for advanced uterine (endometrial) cancer across multiple patient groups.
Why this matters for patients
Large cancer meetings like ASCO can feel overwhelming, especially when headlines begin circulating before patients fully understand what the research may mean for them personally. Not every study presented at ASCO will immediately change patient care, and promising early results don’t always become a new standard of treatment. However, these meetings offer an important look at where uterine (endometrial) cancer research and future treatment strategies are moving, including:
- Expansion of immunotherapy in frontline treatment
- Greater use of biomarker testing
- More personalized treatment strategies
- Growing interest in targeted therapies and combination approaches
- Longer-term focus on survival and durable disease control
For patients, staying informed can help support more meaningful conversations with your healthcare team and a better understanding of how treatment options continue to evolve.
Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.
